You are viewing an incomplete version of our website. Please click to reload the website as full version.

Cystatin C (CST3) antibody

Details for Product No. ABIN1045447, Supplier: Login to see New
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Synonyms armd11, fb51d07, wu:fb24g06, wu:fb51d07, wu:fc55f03, zgc:136227, ARMD11, CysC, CYSC
(336), (73), (39), (8), (7), (4), (2), (2), (1), (1)
(167), (157), (75), (18), (3), (2)
(28), (23), (18), (5), (5), (5), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1)
ELISA, Western Blotting (WB)
(281), (223), (54), (35), (18), (16), (15), (11), (10), (9), (9), (8), (8), (7), (4), (4), (3), (2), (2), (2), (2), (1), (1), (1), (1), (1)
Pubmed 17 references available
Supplier Login to see New
Catalog number from supplier Login to see New
Quantity 100 μg
Shipping to United States ( )
Availability Will be delivered in 9 to 11 Business Days
Immunogen Recombinant Human Cystatin C protein
Isotype IgG2b
Specificity Specific for Human Cystatin C denatured and native forms
Purification Caprylic Acid Ammonium Sulfate Precipitation
Alternative Name Cystatin C (CST3 Antibody Abstract)
Background Defects in CST3 are the cause of amyloidosis type 6 (AMYL6) [MIM:105150], also known as hereditary cerebral hemorrhage with amyloidosis (HCHWA), cerebral amyloid angiopathy (CAA) or cerebroarterial amyloidosis Icelandic type. AMYL6 is a hereditary generalized amyloidosis due to cystatin C amyloid deposition. Cystatin C amyloid accumulates in the walls of arteries, arterioles, and sometimes capillaries and veins of the brain, and in various organs including lymphoid tissue, spleen, salivary glands, and seminal vesicles. Amyloid deposition in the cerebral vessels results in cerebral amyloid angiopathy, cerebral hemorrhage and premature stroke. Cystatin C levels in the cerebrospinal fluid are abnormally low.Genetic variations in CST3 are associated with age-related macular degeneration type 11 (ARMD11) [MIM:611953]. ARMD is a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane.
Synonyms: CysC,Cystatin-3,Gamma-trace,Neuroendocrine basic polypeptide,Post-gamma-globulin
UniProt P01034
Research Area Cardiovascular, Atherosclerosis, Apoptosis/Necrosis, Serum/Plasma Proteins
Application Notes Not yet tested in other applications. Optimal working dilutions should be determined experimentally by the investigator.

Other species are not tested. Please decide the specificity by homology

Restrictions For Research Use only
Format Liquid
Buffer 0.03 % Proclin 300, 50 % Glycerol, 0.01 M PBS, pH 7.4
Preservative ProClin
Precaution of Use This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
Handling Advice Avoid freeze and thaw cycles.
Storage -20 °C
Storage Comment Shipped at 4 °C Upon delivery aliquot and store at -24 °C or -84 °C.
Product cited in: López Gómez, Sacristán Enciso, Micó et al.: "Serum cystatin C and microalbuminuria in the detection of vascular and renal damage in early stages." in: Nefrología : publicación oficial de la Sociedad Española Nefrologia, Vol. 31, Issue 5, pp. 560-6, 2011 (PubMed).

Warwas, Piwowar: "[Urinary cystatin C as a biomarker of renal tubular injury]." in: Postȩpy higieny i medycyny doświadczalnej (Online), Vol. 65, pp. 562-8, 2011 (PubMed).

Ito, Pacold, Durazo-Arvizu et al.: "The effect of including cystatin C or creatinine in a cardiovascular risk model for asymptomatic individuals: the multi-ethnic study of atherosclerosis." in: American journal of epidemiology, Vol. 174, Issue 8, pp. 949-57, 2011 (PubMed).

Reznichenko, Panphilova, Evdokimova et al.: "[Cystatin C level is independently related to risk of unfavorable outcome after acute coronary syndrome in individuals with normal or moderately reduced renal function]." in: Kardiologiia, Vol. 51, Issue 6, pp. 4-10, 2011 (PubMed).

Targońska-Stepniak, Majdan: "Cystatin C concentration is correlated with disease activity in rheumatoid arthritis patients." in: Scandinavian journal of rheumatology, Vol. 40, Issue 5, pp. 341-6, 2011 (PubMed).

Spanaus, Kollerits, Ritz et al.: "Serum creatinine, cystatin C, and beta-trace protein in diagnostic staging and predicting progression of primary nondiabetic chronic kidney disease." in: Clinical chemistry, Vol. 56, Issue 5, pp. 740-9, 2010 (PubMed).

Borges, Hirota, Quinto et al.: "Is cystatin C a useful marker in the detection of diabetic kidney disease?" in: Nephron. Clinical practice, Vol. 114, Issue 2, pp. c127-34, 2010 (PubMed).

Shlipak, Katz, Kestenbaum et al.: "Rate of kidney function decline in older adults: a comparison using creatinine and cystatin C." in: American journal of nephrology, Vol. 30, Issue 3, pp. 171-8, 2009 (PubMed).

Muntner, Vupputuri, Coresh et al.: "Metabolic abnormalities are present in adults with elevated serum cystatin C." in: Kidney international, Vol. 76, Issue 1, pp. 81-8, 2009 (PubMed).

Delanaye, Cavalier, Radermecker et al.: "Cystatin C or creatinine for detection of stage 3 chronic kidney disease in anorexia nervosa." in: Nephron. Clinical practice, Vol. 110, Issue 3, pp. c158-63, 2008 (PubMed).

Hojs, Bevc, Ekart et al.: "Serum cystatin C-based equation compared to serum creatinine-based equations for estimation of glomerular filtration rate in patients with chronic kidney disease." in: Clinical nephrology, Vol. 70, Issue 1, pp. 10-7, 2008 (PubMed).

Yang, Peng, Lin et al.: "Use of serum cystatin C to detect early decline of glomerular filtration rate in type 2 diabetes." in: Internal medicine (Tokyo, Japan), Vol. 46, Issue 12, pp. 801-6, 2007 (PubMed).

Pucci, Triscornia, Lucchesi et al.: "Cystatin C and estimates of renal function: searching for a better measure of kidney function in diabetic patients." in: Clinical chemistry, Vol. 53, Issue 3, pp. 480-8, 2007 (PubMed).

Shlipak, Katz, Sarnak et al.: "Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease." in: Annals of internal medicine, Vol. 145, Issue 4, pp. 237-46, 2006 (PubMed).

Hojs, Bevc, Ekart et al.: "Serum cystatin C as an endogenous marker of renal function in patients with mild to moderate impairment of kidney function." in: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 21, Issue 7, pp. 1855-62, 2006 (PubMed).

Mussap, Dalla Vestra, Fioretto et al.: "Cystatin C is a more sensitive marker than creatinine for the estimation of GFR in type 2 diabetic patients." in: Kidney international, Vol. 61, Issue 4, pp. 1453-61, 2002 (PubMed).

Basile, Drüeke, Lacour et al.: "Total parathyroidectomy and delayed parathyroid autotransplantation using a simplified cryopreservation technique: human and animal studies." in: American journal of kidney diseases : the official journal of the National Kidney Foundation, Vol. 3, Issue 5, pp. 366-70, 1984 (PubMed).

Catalog No. ABIN1045447
Plus shipping costs $45.00

Order hotline:

  • +1 877 302 8632
  • +1 888 205 9894 (TF)